Thank you, Mr. Chairman. I have just a couple of questions.
I think everybody has been very clear in this panel and in the previous panel that patient safety is, first and foremost, the issue that we're all supporting, and also that we're trying to stop the transmission of disease and that we don't want to see that happen through a transplant process.
I think everybody has also talked about the science of the decision and that the decision needs to be based on good science. I want to come back to that a little bit, because I think, Dr. Levy, you cited some HIV statistics that were quite a bit different from what Ms. Gillham-Eisen talked about.
So I'd like to ask her if she could comment on this, please.